Overview

This is a summary of the European public assessment report (EPAR) for Zoely. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zoely.

Zoely is a medicine available as 24 white ‘active’ tablets that contain the active substances nomegestrol acetate (2.5 mg) and estradiol (1.5 mg), and four yellow ‘inactive’ (placebo) tablets that do not contain any active substance.

Zoely is a contraceptive pill. The medicine can only be obtained with a prescription.

One tablet a day is taken for as long as contraception is required, starting with an active tablet on the first day of the cycle. Zoely comes in blisters containing 28 tablets (24 white tablets followed by 4 yellow tablets), which are taken in sequence using stickers to identify the days of the week for each tablet.

Zoely is a combined contraceptive pill that contains two active substances, nomegestrol acetate (a progestogen) and estradiol (an oestrogen). Estradiol is the same as a hormone naturally produced by the ovaries during a menstrual cycle. Nomegestrol acetate is derived from the hormone called progesterone which is also produced by the ovaries during a menstrual cycle. Zoely works by changing the body’s hormonal balance to prevent ovulation, by altering the cervical mucus and by thinning the endometrium (the lining of the womb).

Zoely was investigated in two main studies involving a total of 4,433 women aged 18 to 50 years old. The participants were given either Zoely or another contraceptive pill containing drospirenone and ethinyl estradiol for one year (13 menstrual cycles). The main measure of effectiveness was the number of women aged 18 to 35 who became pregnant during or shortly after treatment, expressed in terms of a pregnancy rate using the ‘Pearl Index’. The Pearl Index is a standard way of measuring the effectiveness of contraceptives, which measures how many unwanted pregnancies occur in 100 women-years (corresponding to 1,300 menstrual cycles). A lower Pearl Index represents a lower chance of getting pregnant.

No clinical study data on Zoely are available in adolescents under 18 years old.

In women aged 18 to 35, the Pearl Index was around 0.4 with Zoely and 0.8 with the comparator medicine in the first study, and around 1.2 with Zoely and 1.9 with the comparator medicine in the second study.

The most frequent side effects with Zoely (seen in more than 1 user in 10) are acne and changes to menstrual periods (e.g. absence or irregularity). For the full list of all side effects reported with Zoely, see the package leaflet.

Zoely must not be used when a woman has, or has had, blood clots in the veins or arteries or when a woman has some of the risk factors for blood clots. It should not be used in women who have pancreatitis (inflammation of the pancreas), severe liver problems, liver tumours or a history of liver tumours, certain types of cancer, or abnormal bleeding from the genital area whose cause has not been diagnosed. For the full list of restrictions, see the package leaflet.

The CHMP decided that the benefits of Zoely are greater than its risks and recommended that it be given marketing authorisation.

A risk management plan has been developed to ensure that Zoely is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Zoely, including the appropriate precautions to be followed by healthcare professionals and patients.

In addition, the company will perform a study to further investigate the risk of blood clots.

The European Commission granted a marketing authorisation valid throughout the European Union for Zoely on 27 July 2011.

For more information about treatment with Zoely, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Zoely : EPAR - Summary for the public

български (BG) (101.94 KB - PDF)
español (ES) (76.07 KB - PDF)
čeština (CS) (100.43 KB - PDF)
dansk (DA) (75.17 KB - PDF)
Deutsch (DE) (76.68 KB - PDF)
eesti keel (ET) (84.19 KB - PDF)
ελληνικά (EL) (104.05 KB - PDF)
français (FR) (76.14 KB - PDF)
hrvatski (HR) (94.84 KB - PDF)
italiano (IT) (75.69 KB - PDF)
latviešu valoda (LV) (97.5 KB - PDF)
lietuvių kalba (LT) (99.01 KB - PDF)
magyar (HU) (96.35 KB - PDF)
Malti (MT) (99.83 KB - PDF)
Nederlands (NL) (75.79 KB - PDF)
polski (PL) (101.6 KB - PDF)
português (PT) (76.27 KB - PDF)
română (RO) (97.14 KB - PDF)
slovenčina (SK) (99.62 KB - PDF)
slovenščina (SL) (94 KB - PDF)
Suomi (FI) (74.76 KB - PDF)
svenska (SV) (75.38 KB - PDF)

Zoely : EPAR - Risk-management-plan summary

Product information

Zoely : EPAR - Product Information

български (BG) (860.1 KB - PDF)
español (ES) (507 KB - PDF)
čeština (CS) (796.63 KB - PDF)
dansk (DA) (590.62 KB - PDF)
Deutsch (DE) (646.08 KB - PDF)
eesti keel (ET) (681.81 KB - PDF)
ελληνικά (EL) (797.54 KB - PDF)
français (FR) (812.41 KB - PDF)
hrvatski (HR) (674.48 KB - PDF)
íslenska (IS) (552.61 KB - PDF)
italiano (IT) (621.25 KB - PDF)
latviešu valoda (LV) (780.18 KB - PDF)
lietuvių kalba (LT) (762.39 KB - PDF)
magyar (HU) (759.42 KB - PDF)
Malti (MT) (768.56 KB - PDF)
Nederlands (NL) (526.13 KB - PDF)
norsk (NO) (552.36 KB - PDF)
polski (PL) (773.28 KB - PDF)
português (PT) (651.25 KB - PDF)
română (RO) (817.84 KB - PDF)
slovenčina (SK) (743.44 KB - PDF)
slovenščina (SL) (871.86 KB - PDF)
Suomi (FI) (748.83 KB - PDF)
svenska (SV) (665.77 KB - PDF)

Latest procedure affecting product information: A31/0060

28/11/2022

Globe icon

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

Zoely : EPAR - All Authorised presentations

български (BG) (45.78 KB - PDF)
español (ES) (13.74 KB - PDF)
čeština (CS) (26.75 KB - PDF)
dansk (DA) (13.38 KB - PDF)
Deutsch (DE) (13.53 KB - PDF)
eesti keel (ET) (13.95 KB - PDF)
ελληνικά (EL) (43.72 KB - PDF)
français (FR) (13.71 KB - PDF)
íslenska (IS) (13.7 KB - PDF)
italiano (IT) (13.28 KB - PDF)
latviešu valoda (LV) (42.94 KB - PDF)
lietuvių kalba (LT) (43.18 KB - PDF)
magyar (HU) (26.86 KB - PDF)
Malti (MT) (41.49 KB - PDF)
Nederlands (NL) (13.19 KB - PDF)
norsk (NO) (13.41 KB - PDF)
polski (PL) (43.95 KB - PDF)
português (PT) (13.72 KB - PDF)
română (RO) (41.72 KB - PDF)
slovenčina (SK) (27.2 KB - PDF)
slovenščina (SL) (13.77 KB - PDF)
Suomi (FI) (13.75 KB - PDF)
svenska (SV) (13.69 KB - PDF)

Product details

Name of medicine
Zoely
Active substance
  • Nomegestrol acetate
  • estradiol
International non-proprietary name (INN) or common name
  • nomegestrol
  • estradiol
Therapeutic area (MeSH)
Contraception
Anatomical therapeutic chemical (ATC) code
G03AA14

Pharmacotherapeutic group

Sex hormones and modulators of the genital system

Therapeutic indication

Oral contraception

Authorisation details

EMA product number
EMEA/H/C/001213
Marketing authorisation holder
Theramex Ireland Limited

3rd Floor, Kilmore House
Park Lane, Spencer Dock
Dublin 1, D01 YE64
Ireland

Marketing authorisation issued
26/07/2011
Revision
23

Assessment history

Zoely : EPAR - Procedural steps taken and scientific information after authorisation

Zoely-H-A-31-1510-C-1213-60 : EPAR - Divergent positions to CHMP opinion

Zoely-H-A-31-1510-C-1213-60 : EPAR - Assessment report

Zoely-H-C-001213-PSUSA-2182-202101 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Zoely-H-C-001213-SW-0058 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Zoely-H-C-1213-0000 : EPAR - Assessment Report

Zoely-H-C-1213-A31-1356 : EPAR - Assessment Report - Article 31

Zoely : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisations, and detailed explanation for the differences from the PRAC recommendation. CHMP members’ divergent positio...

български (BG) (76.22 KB - PDF)
español (ES) (35.4 KB - PDF)
čeština (CS) (72.6 KB - PDF)
dansk (DA) (33.73 KB - PDF)
Deutsch (DE) (37.7 KB - PDF)
eesti keel (ET) (37.02 KB - PDF)
ελληνικά (EL) (73.63 KB - PDF)
français (FR) (34.61 KB - PDF)
hrvatski (HR) (62.45 KB - PDF)
italiano (IT) (35.77 KB - PDF)
latviešu valoda (LV) (64.93 KB - PDF)
lietuvių kalba (LT) (68.02 KB - PDF)
magyar (HU) (62.49 KB - PDF)
Malti (MT) (70.71 KB - PDF)
Nederlands (NL) (34.89 KB - PDF)
polski (PL) (66.13 KB - PDF)
português (PT) (34.24 KB - PDF)
română (RO) (68.62 KB - PDF)
slovenčina (SK) (66.05 KB - PDF)
slovenščina (SL) (63.5 KB - PDF)
Suomi (FI) (32.48 KB - PDF)
svenska (SV) (35 KB - PDF)

Zoely-H-C-1213-PSU-0005 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Zoely : EPAR - Public assessment report

CHMP summary of positive opinion for Zoely

Topics

This page was last updated on

How useful do you find this page?